SLAMF7 and glioma: Collectively, these findings verify that the IL‐12 and nCD47‐SLAMF7 combination can effectively modulate the tumor‐suppressive microenvironment and significantly increase the infiltration of anti‐tumor effector T cells, consequently inhibiting glioma progression.